Prescription Medicines
TenelyM SR Tab. 10/750mg
- Product Category
- Diabetes treatment
- Active Ingredients
- Teneligliptin, metformin hydrochloride
- Appearance
- Yellow, biconvex, oval-shaped, sustained-release film-coated tablets
- Reimbursement Code
- 648104800
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredients:
Teneligliptin hydrochloride hydrate (in-house specification) ----- 12.98mg (10mg as teneligliptin)
Metformin hydrochloride (in-house specification) ----- 750.00mg
- Additives: Magnesium stearate, Opadry yellow (200F520056), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, povidone, hypromellose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of teneligliptin and metformin.
3. Dosage and dosage
The dosage of this drug is determined based on each patient's current treatment, effectiveness, and tolerability. This drug is generally administered once a day with dinner, and the dosage is adjusted stepwise to reduce gastrointestinal side effects related to metformin.
This 20/1000mg sustained-release tablet is taken once a day, one tablet at a time.
Patients taking this drug's 10/750mg or 10/500mg extended-release tablets should take 2 tablets at a time, once a day.
In patients who cannot achieve sufficient glycemic control with metformin monotherapy, the initial dose of this drug should be teneligliptin 20 mg once daily and the existing dose of metformin. In patients switching from combination therapy with teneligliptin and metformin to this drug, the dose of this drug can be started at the existing dose of teneligliptin and metformin. When switching from metformin immediate-release to sustained-release formulations, glycemic control should be closely monitored and dosage adjustments should be made appropriately. When coadministered with sulfonylurea, a reduction in sulfonylurea may be considered to reduce the risk of hypoglycemia.
The maximum recommended daily dose is 20 mg of teneligliptin and 2000 mg of sustained-release metformin.
The safety and effectiveness of this drug have not been specifically evaluated in patients switching to this drug from other hypoglycemic agents. Any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring because they may cause changes in glycemic control.
To maintain its sustained-release properties, this medication should be swallowed without breaking, crushing, grinding, or chewing.
4. Precautions for use
1. Warning
metformin hydrochloride
1) In very rare cases, severe lactic acidosis may occur. Cases of death due to lactic acidosis have been reported.
2) When administered concurrently with other antidiabetic agents such as insulin and sulfonylureas drugs, severe hypoglycemia may occur in rare cases.
2. Do not administer to the following patients
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2). Patients with kidney disease or renal dysfunction (serum creatinine level greater than 1.5 mg/dL in men or greater than 1.4 mg/dL in women, or abnormal creatinine clearance) that may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with congestive heart failure requiring drug treatment
3) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g., intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure and are associated with lactic acidosis in patients receiving this drug. Therefore, in patients scheduled for such tests, this drug should be stopped at least 48 hours before administration, and renal function should be reevaluated after 48 hours and found to be normal. Only then do treatment resume.
4) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
5) Diabetic precoma
6) Patients with a history of hypersensitivity to the ingredients of this drug or biguanide drugs
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women or women who may be pregnant
3. Administer with caution to the following patients:
1) The following patients or conditions (may cause hypoglycemia)
(1) Patients taking sulfonylurease or insulin
(2) Irregular meal intake, insufficient meal intake
(3) Patients who performed vigorous muscle exercise
2) Patients with a past history of abdominal surgery or intestinal obstruction
3) Patients prone to QT interval prolongation (patients with arrhythmia such as severe bradycardia or previous medical history, patients with heart disease such as congestive heart failure, patients with hypokalemia, etc.): There is a risk of side effects such as QT interval prolongation, so it is recommended to avoid administration in patients with QT interval prolongation or history (congenital long QT interval syndrome, etc.), or patients with a history of torsade de pointes.
4) Pancreatitis: Acute pancreatitis was not reported in Japanese and domestic clinical trials, but one case of acute pancreatitis was reported in European clinical trials and acute pancreatitis was reported after marketing in Japan. Therefore, patients should be informed to seek professional diagnosis from a doctor if characteristic symptoms of acute pancreatitis, such as persistent severe abdominal pain and vomiting, appear. If pancreatitis is suspected after starting treatment, administration of teneligliptin and other suspected drugs should be discontinued (see “Serious Adverse Drug Reactions”).
4. Adverse reactions (Tenelia M-sero-release tablets)
<Teneligliptin>
(1) Foreign (Japanese) clinical trial results and post-marketing safety information
In a foreign (Japanese) clinical trial, out of a total of 1,645 people who took teneligliptin for more than 4 weeks, 156 (9.5%) had 232 adverse drug reactions (including abnormal clinical test values). Major adverse drug reactions included hypoglycemia in 43 patients (2.6%) and constipation in 14 patients (0.9%).
1) Serious adverse drug reactions
low blood sugar
When used in combination with other diabetes drugs, hypoglycemia may occur (8.9% when used in combination with glimepiride, 1.5% when used in combination with pioglitazone, 3.8% when used in combination with meglitinides, 1.1% when used in combination with biguanides, and 1.3% when used in combination with α-glucosidase inhibitors). Additionally, there have been reports of hypoglycemia (1.1%) even when other diabetes drugs were not used together. If symptoms of hypoglycemia appear, take appropriate measures, such as consuming foods containing carbohydrates. When used in combination with α-glucosidase inhibitors, glucose must be administered.
Intestinal obstruction (0.1%)
As intestinal obstruction may occur, observe thoroughly. If abnormalities such as severe constipation, abdominal distension, persistent abdominal pain, or vomiting appear, discontinue administration and take appropriate measures.
Liver dysfunction (incidence unknown, post-marketing safety information)
Liver dysfunction (elevated AST (GOT), ALT (GPT), etc.) may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if suspected.
Interstitial pneumonia (incidence unknown, postmarketing safety information)
Interstitial pneumonia may occur, so if coughing, shortness of breath, fever, or abnormal lung sounds (crepitus) are observed, appropriate tests such as chest X-ray and chest CT should be promptly performed. If interstitial pneumonia is suspected, discontinue administration and take appropriate measures, such as administration of corticosteroids.
Pemphigus vulgaris (incidence unknown, post-marketing safety information)
Pemphigus vulgaris may occur, so if blisters or erosions are observed, consult a dermatologist and take appropriate measures, such as discontinuing administration.
Acute pancreatitis (incidence unknown, post-marketing safety information)
Acute pancreatitis may occur. Patients should be carefully observed, and if abnormalities such as persistent severe abdominal pain and vomiting are observed, administration of this drug should be discontinued and appropriate treatment should be taken (see “Careful administration” section).
2) Other adverse drug reactions
If adverse drug reactions occur, take appropriate measures, such as discontinuing administration.
Table 1. Other adverse drug reactions
*Table: Refer to manual
(2) Domestic clinical trial results
1) Teneligliptin and metformin combination therapy
The safety of a total of 205 subjects was analyzed in a double-blind, parallel group, randomized, placebo-controlled clinical trial conducted in Korea.
During the 16-week clinical trial period, the adverse reaction rate was 44.9% (31/69 people) in the placebo and metformin combination group and 41.2% (56/136 people) in the teneligliptin and metformin combination group. The adverse reaction rate was 1.4% (1/69 people) in the placebo and metformin combination group and teneligliptin and metformin combination treatment group. The combined treatment group was 3.7% (5/136 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were diarrhea, epigastric pain, hepatic steatosis, liver failure, edema, and rash. As a result of the clinical trial, adverse reactions reported at a frequency of 1% or more, which occurred more frequently in patients receiving teneligliptin and metformin than in patients receiving placebo and metformin, are shown in Table 2.
Table 2. Results of teneligliptin combination therapy (metformin) clinical trials: Adverse reactions reported at a frequency of 1% or more (regardless of investigator causality assessment) that occurred more frequently in patients receiving teneligliptin and metformin than in patients receiving placebo and metformin
*Table: Refer to manual
2) Metformin and glimepiride combination therapy
The safety of a total of 200 subjects was analyzed in a multicenter, randomized, double-blind, non-inferiority, active-controlled, phase 3 clinical trial conducted in Korea.
During the 24-week clinical trial period, the adverse reaction rate was 62.24% (61/98 people) in the active control drug combination group and 61.76% (63/102 people) in the teneligliptin combination treatment group, and the adverse reaction rate was 40.82% (40/98 people) in the active control drug combination group and teneligliptin combination treatment group. It was 45.10% (46/102 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were hypoglycemia, dizziness, tremors, headache, asthenia, hunger, fatigue, facial swelling, diarrhea, indigestion, constipation, nausea, viral upper respiratory infection, shingles, rhinitis, cold sweat, itching, diabetic retinopathy, decreased vision, cough, pulmonary congestion, difficulty breathing, drug overdose, and prostatic hyperplasia. As a result of the clinical trial, adverse reactions reported at a frequency of more than 1% occurred more frequently in the teneligliptin combination treatment group than in the active comparator combination treatment group, and are shown in Table 3.
Table 3. As a result of clinical trials of this drug's combination therapy (metformin and glimepiride), adverse reactions reported at a frequency of more than 1% occurred more frequently in the teneligliptin combination treatment group than in the active comparator combination treatment group (regardless of the researcher's causality assessment).
*Table: Refer to manual
3) Hypoglycemia confirmed as a result of domestic clinical trials
Teneligliptin monotherapy clinical trial results showed that among 142 test subjects, only 1 subject (2.3%) in the placebo group experienced hypoglycemia, and the reported case was classified as a case of suspected hypoglycemia. Results of clinical trials for metformin combination therapy Among 205 test subjects, the subjects who experienced hypoglycemia were 2 (2.9%) in the metformin and placebo combination group and 4 (2.9%) in the metformin and teneligliptin combination group, and all were classified as suspected cases of hypoglycemia. In the clinical trial of the combination therapy of metformin and glimepiride, self-blood sugar was measured at least once a day and collected as hypoglycemia until it was reported as ‘asymptomatic hypoglycemia symptoms.’ Among the 200 test subjects, the subjects who experienced hypoglycemia excluding ‘asymptomatic hypoglycemia symptoms’ were the group that received metformin, glimepiride, and teneligliptin in combination. There were 21 patients (20.59%), and 19 patients (19.39%) in the group administered metformin, glimepiride, and active control drug together. When ‘asymptomatic hypoglycemia symptoms’ were included, there were 32 patients (31.37%) in the group administered metformin, glimepiride, and teneligliptin in combination, and 28 patients (28.57%) in the group administered metformin, glimepiride, and active control drug in combination. Among the reported hypoglycemias, severe hypoglycemia occurred in one person each in the test and control groups.
(3) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,042 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.54% (199/3,042 people, 263 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
*Table: Refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to manual
<Additional information on individual ingredients>
teneligliptin
The safety of a total of 142 subjects was analyzed in a randomized, double-blind, parallel group, placebo-controlled, phase 3 clinical trial conducted in Korea.
During the 24 weeks of the clinical trial, the adverse reaction rate was 45.45% (20/44 people) in the placebo group and 29.59% (29/98 people) in the teneligliptin group, and the adverse reaction rate was 6.82% (3/44 people) in the placebo group and 1.02% (1/98 people) in the teneligliptin group. The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. The adverse drug reaction was dyslipidemia. As a result of clinical trials, adverse reactions reported at a frequency of 2% or more, which occurred more frequently in patients receiving teneligliptin than in patients receiving placebo, are shown in Table 4.
Table 4. Teneligliptin monotherapy clinical trial results, adverse reactions reported at a frequency of 2% or more occurred more frequently in patients receiving teneligliptin compared to placebo (regardless of investigator causality assessment)
*Table: Refer to manual
metformin hydrochloride
In placebo-controlled monotherapy trials of extended-release metformin, diarrhea and nausea/vomiting were reported in >5% of metformin-treated patients and more commonly in placebo-controlled patients (diarrhea 9.6% vs 2.6%, nausea/vomiting 6.5% vs 1.5%). Diarrhea caused discontinuation of the test drug in 0.6% of patients receiving sustained-release metformin.
Additionally, metformin may lower serum vitamin B12 concentrations. It is recommended that patients taking this drug undergo a hematological test every year, and if there are any obvious abnormalities, they should be appropriately investigated and managed.
<Domestic post-marketing survey results>
As a result of a post-marketing survey conducted on 633 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.0% (38/633 people, 54 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to causal relationships are listed in the table below according to frequency of occurrence, and no serious adverse drug reactions for which causal relationships cannot be ruled out were reported.
*Table: Refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to manual
5. General precautions
1) Lactic acidosis
Lactic acidosis is a rare but serious metabolic complication that occurs due to accumulation of metformin hydrochloride during treatment. In 50% of cases it occurs, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin hydrochloride is believed to be the cause of lactic acidosis, the blood concentration of metformin hydrochloride is generally found to exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin hydrochloride (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple internal and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin hydrochloride should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so metformin hydrochloride is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to cause metformin hydrochloride to affect lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while receiving metformin hydrochloride.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin hydrochloride concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a certain dose of metformin hydrochloride, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin hydrochloride do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient receiving metformin hydrochloride, the drug should be discontinued immediately and general supportive therapy should be immediately administered. Since metformin hydrochloride is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Monitoring of renal function
Metformin is mostly excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal dysfunction. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), discontinue treatment. Special caution is needed in situations that may lead to rapid renal function impairment, such as those experiencing dehydration (severe or persistent vomiting or diarrhea) or starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
3) Liver dysfunction
The administration of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Therefore, this drug is not administered to patients with hepatic impairment.
4) Diabetes-like symptoms
Application is considered only for patients with confirmed type 2 diabetes. Please note that in addition to diabetes, there are diseases that show diabetes-like symptoms (nephrogenic diabetes, abnormal thyroid function, etc.), such as impaired glucose tolerance and positive urine glucose.
5) Hypoxia state
Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia have been associated with lactic acidosis with metformin administration and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
6) Alcohol consumption
Alcohol is known to increase the effect of metformin hydrochloride on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level
In clinical trials lasting 29 weeks, approximately 7% of patients receiving metformin hydrochloride were observed to have normal serum vitamin B12 levels decline below normal before the trial, without clinical symptoms. However, this decrease is possible because it interferes with B12 absorption from the B12-intrinsic factor complex, has little correlation with anemia, and is quickly recovered by discontinuing metformin hydrochloride administration or supplementing with vitamin B12. Patients receiving metformin hydrochloride should have their hematological values checked annually, and obvious abnormal values should be appropriately evaluated and managed. Certain individuals (those with inadequate intake or absorption of vitamin B12 or calcium) may be predisposed to having vitamin B12 levels below normal. For these patients, it may be useful to have regular serum vitamin B12 measurements at 2-3 year intervals.
8) Changes in controlled diabetes patients
If a patient whose type 2 diabetes was previously well controlled with this drug develops abnormal laboratory findings or clinical disease (especially vague and poorly defined disease), the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin hydrochloride levels are tested. If any form of acidosis appears, immediately stop administering metformin hydrochloride and take other appropriate and correct measures.
9) Concurrent administration with drugs known to cause hypoglycemia
If this drug is used together with insulin secretion stimulants such as insulin and sulfonylureas, the incidence of hypoglycemia may increase. When used in combination with sulfonylurea drugs or insulin, a reduction in the amount of sulfonylurea drugs or insulin may be considered to reduce the risk of hypoglycemia. When using this medicine, fully explain to the patient the symptoms of hypoglycemia and how to deal with it.
10) Patients from specific occupations
Metformin, one of the ingredients of this drug, may rarely cause severe lactic acidosis and severe delayed hypoglycemia, so caution should be exercised when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
In rare cases, it may cause severe lactic acidosis and severe delayed hypoglycemia, so caution should be exercised when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
11) Concomitant medications that affect renal function or metformin distribution
Concomitant medications that affect metformin distribution, such as cationic drugs that affect renal function, cause significant hemodynamic changes, or are eliminated by renal tubular secretion, should be administered with caution.
12) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking other DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
13) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and a dermatologist should be consulted for diagnosis and appropriate treatment.
6. Interaction
Studies on the pharmacokinetic drug interactions of this drug have not been conducted, but studies have been conducted on teneligliptin and metformin, respectively.
teneligliptin
Teneligliptin is mainly metabolized by CYP3A4 and flavin-containing monooxygenase (FMO1 and FMO3), and the excretion rate of unmetabolized teneligliptin through urine was 14.8-22.1%.
1) Ketoconazole: When ketoconazole, a strong CYP3A4 inhibitor and P-gp inhibitor, was coadministered with 20 mg of teneligliptin, the AUC and Cmax of teneligliptin increased by 1.49-fold and 1.37-fold, respectively.
2) Metformin: When teneligliptin 40mg and metformin were administered together, metformin did not significantly change the pharmacokinetics of teneligliptin. In addition, by co-administering teneligliptin, the AUC of metformin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.209 [1.143∼1.278]), but Cmax did not change. It is thought unlikely that teneligliptin will have a significant effect on the pharmacokinetics of metformin.
3) Sulfonylurea: When teneligliptin 40mg and glimepiride were co-administered, no drug interaction between teneligliptin and glimepiride was confirmed.
4) Thiazolidinedione: When teneligliptin 40mg and pioglitazone were co-administered, teneligliptin did not significantly change the pharmacokinetics of pioglitazone and its active metabolites (M-III and M-IV). In addition, the Cmax of teneligliptin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.117 [0.984∼1.266]) by co-administering pioglitazone, but the AUC did not change. There appears to be little effect of coadministration with pioglitazone on the pharmacokinetics of teneligliptin.
5) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be further increased by drugs that increase the blood sugar lowering effect such as β-blockers, salicylates, and MAO inhibitors, so it should be administered while sufficiently observing the blood sugar level and patient condition.
6) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be reduced by drugs that reduce the blood sugar lowering effect such as adrenaline, corticosteroids, and thyroid hormones, so it should be administered while sufficiently observing the blood sugar level and patient condition.
7) There is a risk of QT interval prolongation when coadministered with arrhythmia drugs of class IA (e.g., quinidine, procainamide) or group III (e.g., amiodarone, sotalol) that may cause QT interval prolongation.
metformin hydrochloride
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, angiotensin converting enzyme inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.),
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and potentially expose patients to the risk of lactic acidosis. Metformin administration should be discontinued before or at the time of testing using iodine-labeled contrast media, and administered again at least 48 hours later and after confirmation of normal renal function.
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin hydrochloride and glyburide did not change the pharmacokinetics or pharmacodynamic properties of metformin hydrochloride. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose metformin hydrochloride in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction of metformin hydrochloride and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin hydrochloride without significant changes in the renal clearance of metformin hydrochloride, and increases blood Cmax by 22% and blood AUC by 15%. When administered together with metformin hydrochloride, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin hydrochloride and furosemide are co-administered chronically.
6) Nifedipine: A study on the drug interaction between metformin hydrochloride and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin hydrochloride in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin hydrochloride. Metformin hydrochloride does not significantly affect nifedipine.
7) Drugs that may affect metformin hydrochloride, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In a single co-administration study in healthy volunteers, the pharmacokinetic properties of metformin hydrochloride and propranolol, and metformin hydrochloride and ibuprofen were not affected by each other. Since the binding of metformin hydrochloride to plasma proteins is negligible, there is little interaction with drugs that bind to proteins in large quantities, such as salicylic acid, sulfonamides, chloramphenicol, and probenecid, compared to sulfonylureas, which bind extensively to plasma proteins.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
Comparative clinical trials in pregnant women have not been conducted for this drug or each of its ingredients. Animal reproductive toxicity tests cannot predict reactions in humans. Therefore, it should not be administered to pregnant women or women who may be pregnant.
teneligliptin
There are no appropriate clinical trial results for pregnant women, so its use in pregnant women is not recommended. This drug has been observed to transfer to the fetus in non-clinical studies (rats).
metformin hydrochloride
Metformin was not teratogenic when administered to rats and rabbits at doses up to 600 mg/kg/day. This represents exposures approximately 2 and 6 times the maximum recommended human dose of 2000 mg based on body surface area comparisons in rats and rabbits, respectively. Partial placental passage of metformin was confirmed by measuring the concentration of the substance in the fetus.
2) Administration to nursing mothers
There have been no studies conducted on lactating animals with this drug combination. It is not known whether teneligliptin or metformin are excreted in human breast milk, but they have been reported to be excreted in breast milk in non-clinical studies (rats). Metformin is excreted in breast milk, and no adverse reactions to metformin have been reported in newborns/infants. However, due to limited reported study results, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in children have not been established (no clinical experience).
9. Administration to elderly people
Metformin is mainly excreted through the kidneys, and renal function tends to decline in the elderly, so the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should have their renal function monitored regularly, and maximum doses are generally not administered to elderly patients.
10. Treatment in case of overdose
teneligliptin
There were no cases of overdose in clinical trials conducted domestically and overseas. The highest dose of teneligliptin used in clinical trials is 320 mg administered to healthy adults for single administration, and 80 mg administered once daily for 7 days for repeated administration to healthy adults. No serious adverse reactions or adverse reactions leading to discontinuation of administration were identified at these doses.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
In patients with end-stage renal failure, 15.6% of the administered teneligliptin dose was removed during hemodialysis.
metformin hydrochloride
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
teneligliptin
1) For teneligliptin, a reverse mutation test using bacteria, a chromosomal abnormality test using CHL/IU cells, a rat micronucleus test, and an irregular DNA synthesis test in rats were conducted. In the chromosomal abnormality test, an increase in structural abnormalities, which appears to be a secondary change in cytotoxicity, was confirmed, but other tests did not cause abnormal mutations, so there appears to be no risk of genotoxicity.
2) As a result of evaluating carcinogenicity using rats and mice, carcinogenicity was not confirmed even at the dose considered to be the maximum tolerated dose (male rat: 75 mg/kg/day, female rat 100 mg/kg/day, mouse: 600 mg/kg/day). The highest doses evaluated in rats and mice represent 65- and 118-fold greater exposure compared to humans at 40 mg/day. The non-toxic dose for non-neoplastic lesions was 10 mg/kg/day and 60 mg/kg/day in rats and mice, respectively (corresponding to approximately 4 times the exposure of 40 mg per day in humans).
3) In a reproductive toxicity test conducted using rats, the non-toxic dose for male and female fertility and reproductive performance was 70 mg/kg/day and 100 mg/kg/day, respectively, which is 11 to 45 times the exposure amount compared to 40 mg/day administered to the human body. In embryo-fetal developmental toxicity tests conducted using rats and rabbits, no teratogenic findings were confirmed in both species, and the non-toxic dose for developmental toxicity is 30 mg/kg/day, which is approximately 11 and 16 times the exposure to humans administered at 40 mg/day. In tests on prenatal and postnatal development and maternal function conducted using rats, the non-toxic dose was 30 mg/kg/day, which is approximately 11 times the exposure amount compared to 40 mg/day administered to humans.
4) In a foreign clinical trial, teneligliptin 160mg was administered repeatedly for 4 days once a day to healthy adults. At this time, placebo-adjusted mean QTc interval prolongation was observed for each individual up to 9.3 msec (90% CI upper limit 13.0 msec). There is no experience in administering more than 160 mg per day in humans.
metformin hydrochloride
1) Metformin is a primary or secondary regenerating drug and does not exhibit pharmacokinetic properties that cause addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (dose lasting 91 weeks) at doses of 900mg/kg/day and 1500mg/kg/day, respectively. This dose is approximately four times the human body's maximum daily allowance based on body surface area. There was no evidence of metformin-related carcinogenicity in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence of the mutagenic potential of this drug in the reverse mutation test (S.typhimurim), gene mutation test (mouse lymphoma cells), chromosomal aberration test (human lymphocytes), or in vivo micronucleus test (mouse bone marrow cells).
Fertility of male and female rats was not affected by metformin when administered at a high dose of 600 mg/kg/day, or approximately 3 times the maximum tolerated dose based on body surface area.
13. Information for experts
1) Pharmacological action
This drug is a combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin.
2) Pharmacokinetic information
A. fasting test
In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Teneri-M 20/1000 mg extended-release tablets (KyungDong Pharm Co., Ltd.), and the reference product, Tenelia-M 20/1000 mg extended-release tablets (Handok Inc.), under fasting conditions. Plasma teneligliptin and metformin concentrations were measured in 38 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
* Table: refer to manual
B. Postprandial test
The test drug Tenelia M extended-release tablets 20/1000 mg [KyungDong Pharm Co., Ltd.] and the control drug Tenelia M extended-release tablets 20/1000 mg [Handok Co., Ltd.] were administered orally once to healthy adults after a meal in a 2 In this case, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
* Table: refer to manual
c. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drugs TeneriM Extended-Release Tablet 10/500 mg [KyungDong Pharm Co., Ltd.] and TeneriM Extended-Release Tablet 10/750 mg [KyungDong Pharm Co., Ltd.] with the reference drug TeneriM Extended-Release Tablet 20/1000 mg [KyungDong Pharm Co., Ltd.], and the dissolution patterns were equivalent to the reference drug. Accordingly, bioequivalence was proven with the relevant data.
3) Clinical trial information (Tenelia M-sero-release tablet)
Add-on combination of teneligliptin to metformin
The efficacy and safety of teneligliptin when combined with metformin were evaluated in a randomized, double-blind, multicenter, placebo-controlled clinical trial involving a total of 207 patients with type 2 diabetes (HbA1c 7% to less than 10%) who had poor glycemic control with metformin monotherapy (daily dose of 1,000 mg or more for 8 weeks or more). Patients were randomly assigned to receive teneligliptin 20 mg or placebo once daily after a 2-week single-blind, placebo run-in period while continuing metformin treatment.
After 16 weeks of treatment, glycated hemoglobin (HbA1c) in the teneligliptin and metformin combination group was statistically significantly reduced compared to the placebo and metformin combination group, and the proportion of patients whose glycated hemoglobin (HbA1c) reached less than 7% was statistically significantly higher than the placebo and metformin combination group [see Table 3].
Table 3. 16-week treatment results in a placebo-controlled clinical trial of the addition of teneligliptin to metformin in patients with type 2 diabetes.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
18 months from date of manufacture
- Active ingredients:
Teneligliptin hydrochloride hydrate (in-house specification) ----- 12.98mg (10mg as teneligliptin)
Metformin hydrochloride (in-house specification) ----- 750.00mg
- Additives: Magnesium stearate, Opadry yellow (200F520056), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, povidone, hypromellose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of teneligliptin and metformin.
3. Dosage and dosage
The dosage of this drug is determined based on each patient's current treatment, effectiveness, and tolerability. This drug is generally administered once a day with dinner, and the dosage is adjusted stepwise to reduce gastrointestinal side effects related to metformin.
This 20/1000mg sustained-release tablet is taken once a day, one tablet at a time.
Patients taking this drug's 10/750mg or 10/500mg extended-release tablets should take 2 tablets at a time, once a day.
In patients who cannot achieve sufficient glycemic control with metformin monotherapy, the initial dose of this drug should be teneligliptin 20 mg once daily and the existing dose of metformin. In patients switching from combination therapy with teneligliptin and metformin to this drug, the dose of this drug can be started at the existing dose of teneligliptin and metformin. When switching from metformin immediate-release to sustained-release formulations, glycemic control should be closely monitored and dosage adjustments should be made appropriately. When coadministered with sulfonylurea, a reduction in sulfonylurea may be considered to reduce the risk of hypoglycemia.
The maximum recommended daily dose is 20 mg of teneligliptin and 2000 mg of sustained-release metformin.
The safety and effectiveness of this drug have not been specifically evaluated in patients switching to this drug from other hypoglycemic agents. Any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring because they may cause changes in glycemic control.
To maintain its sustained-release properties, this medication should be swallowed without breaking, crushing, grinding, or chewing.
4. Precautions for use
1. Warning
metformin hydrochloride
1) In very rare cases, severe lactic acidosis may occur. Cases of death due to lactic acidosis have been reported.
2) When administered concurrently with other antidiabetic agents such as insulin and sulfonylureas drugs, severe hypoglycemia may occur in rare cases.
2. Do not administer to the following patients
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2). Patients with kidney disease or renal dysfunction (serum creatinine level greater than 1.5 mg/dL in men or greater than 1.4 mg/dL in women, or abnormal creatinine clearance) that may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with congestive heart failure requiring drug treatment
3) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g., intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure and are associated with lactic acidosis in patients receiving this drug. Therefore, in patients scheduled for such tests, this drug should be stopped at least 48 hours before administration, and renal function should be reevaluated after 48 hours and found to be normal. Only then do treatment resume.
4) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
5) Diabetic precoma
6) Patients with a history of hypersensitivity to the ingredients of this drug or biguanide drugs
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women or women who may be pregnant
3. Administer with caution to the following patients:
1) The following patients or conditions (may cause hypoglycemia)
(1) Patients taking sulfonylurease or insulin
(2) Irregular meal intake, insufficient meal intake
(3) Patients who performed vigorous muscle exercise
2) Patients with a past history of abdominal surgery or intestinal obstruction
3) Patients prone to QT interval prolongation (patients with arrhythmia such as severe bradycardia or previous medical history, patients with heart disease such as congestive heart failure, patients with hypokalemia, etc.): There is a risk of side effects such as QT interval prolongation, so it is recommended to avoid administration in patients with QT interval prolongation or history (congenital long QT interval syndrome, etc.), or patients with a history of torsade de pointes.
4) Pancreatitis: Acute pancreatitis was not reported in Japanese and domestic clinical trials, but one case of acute pancreatitis was reported in European clinical trials and acute pancreatitis was reported after marketing in Japan. Therefore, patients should be informed to seek professional diagnosis from a doctor if characteristic symptoms of acute pancreatitis, such as persistent severe abdominal pain and vomiting, appear. If pancreatitis is suspected after starting treatment, administration of teneligliptin and other suspected drugs should be discontinued (see “Serious Adverse Drug Reactions”).
4. Adverse reactions (Tenelia M-sero-release tablets)
<Teneligliptin>
(1) Foreign (Japanese) clinical trial results and post-marketing safety information
In a foreign (Japanese) clinical trial, out of a total of 1,645 people who took teneligliptin for more than 4 weeks, 156 (9.5%) had 232 adverse drug reactions (including abnormal clinical test values). Major adverse drug reactions included hypoglycemia in 43 patients (2.6%) and constipation in 14 patients (0.9%).
1) Serious adverse drug reactions
low blood sugar
When used in combination with other diabetes drugs, hypoglycemia may occur (8.9% when used in combination with glimepiride, 1.5% when used in combination with pioglitazone, 3.8% when used in combination with meglitinides, 1.1% when used in combination with biguanides, and 1.3% when used in combination with α-glucosidase inhibitors). Additionally, there have been reports of hypoglycemia (1.1%) even when other diabetes drugs were not used together. If symptoms of hypoglycemia appear, take appropriate measures, such as consuming foods containing carbohydrates. When used in combination with α-glucosidase inhibitors, glucose must be administered.
Intestinal obstruction (0.1%)
As intestinal obstruction may occur, observe thoroughly. If abnormalities such as severe constipation, abdominal distension, persistent abdominal pain, or vomiting appear, discontinue administration and take appropriate measures.
Liver dysfunction (incidence unknown, post-marketing safety information)
Liver dysfunction (elevated AST (GOT), ALT (GPT), etc.) may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if suspected.
Interstitial pneumonia (incidence unknown, postmarketing safety information)
Interstitial pneumonia may occur, so if coughing, shortness of breath, fever, or abnormal lung sounds (crepitus) are observed, appropriate tests such as chest X-ray and chest CT should be promptly performed. If interstitial pneumonia is suspected, discontinue administration and take appropriate measures, such as administration of corticosteroids.
Pemphigus vulgaris (incidence unknown, post-marketing safety information)
Pemphigus vulgaris may occur, so if blisters or erosions are observed, consult a dermatologist and take appropriate measures, such as discontinuing administration.
Acute pancreatitis (incidence unknown, post-marketing safety information)
Acute pancreatitis may occur. Patients should be carefully observed, and if abnormalities such as persistent severe abdominal pain and vomiting are observed, administration of this drug should be discontinued and appropriate treatment should be taken (see “Careful administration” section).
2) Other adverse drug reactions
If adverse drug reactions occur, take appropriate measures, such as discontinuing administration.
Table 1. Other adverse drug reactions
*Table: Refer to manual
(2) Domestic clinical trial results
1) Teneligliptin and metformin combination therapy
The safety of a total of 205 subjects was analyzed in a double-blind, parallel group, randomized, placebo-controlled clinical trial conducted in Korea.
During the 16-week clinical trial period, the adverse reaction rate was 44.9% (31/69 people) in the placebo and metformin combination group and 41.2% (56/136 people) in the teneligliptin and metformin combination group. The adverse reaction rate was 1.4% (1/69 people) in the placebo and metformin combination group and teneligliptin and metformin combination treatment group. The combined treatment group was 3.7% (5/136 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were diarrhea, epigastric pain, hepatic steatosis, liver failure, edema, and rash. As a result of the clinical trial, adverse reactions reported at a frequency of 1% or more, which occurred more frequently in patients receiving teneligliptin and metformin than in patients receiving placebo and metformin, are shown in Table 2.
Table 2. Results of teneligliptin combination therapy (metformin) clinical trials: Adverse reactions reported at a frequency of 1% or more (regardless of investigator causality assessment) that occurred more frequently in patients receiving teneligliptin and metformin than in patients receiving placebo and metformin
*Table: Refer to manual
2) Metformin and glimepiride combination therapy
The safety of a total of 200 subjects was analyzed in a multicenter, randomized, double-blind, non-inferiority, active-controlled, phase 3 clinical trial conducted in Korea.
During the 24-week clinical trial period, the adverse reaction rate was 62.24% (61/98 people) in the active control drug combination group and 61.76% (63/102 people) in the teneligliptin combination treatment group, and the adverse reaction rate was 40.82% (40/98 people) in the active control drug combination group and teneligliptin combination treatment group. It was 45.10% (46/102 people). The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. Adverse drug reactions were hypoglycemia, dizziness, tremors, headache, asthenia, hunger, fatigue, facial swelling, diarrhea, indigestion, constipation, nausea, viral upper respiratory infection, shingles, rhinitis, cold sweat, itching, diabetic retinopathy, decreased vision, cough, pulmonary congestion, difficulty breathing, drug overdose, and prostatic hyperplasia. As a result of the clinical trial, adverse reactions reported at a frequency of more than 1% occurred more frequently in the teneligliptin combination treatment group than in the active comparator combination treatment group, and are shown in Table 3.
Table 3. As a result of clinical trials of this drug's combination therapy (metformin and glimepiride), adverse reactions reported at a frequency of more than 1% occurred more frequently in the teneligliptin combination treatment group than in the active comparator combination treatment group (regardless of the researcher's causality assessment).
*Table: Refer to manual
3) Hypoglycemia confirmed as a result of domestic clinical trials
Teneligliptin monotherapy clinical trial results showed that among 142 test subjects, only 1 subject (2.3%) in the placebo group experienced hypoglycemia, and the reported case was classified as a case of suspected hypoglycemia. Results of clinical trials for metformin combination therapy Among 205 test subjects, the subjects who experienced hypoglycemia were 2 (2.9%) in the metformin and placebo combination group and 4 (2.9%) in the metformin and teneligliptin combination group, and all were classified as suspected cases of hypoglycemia. In the clinical trial of the combination therapy of metformin and glimepiride, self-blood sugar was measured at least once a day and collected as hypoglycemia until it was reported as ‘asymptomatic hypoglycemia symptoms.’ Among the 200 test subjects, the subjects who experienced hypoglycemia excluding ‘asymptomatic hypoglycemia symptoms’ were the group that received metformin, glimepiride, and teneligliptin in combination. There were 21 patients (20.59%), and 19 patients (19.39%) in the group administered metformin, glimepiride, and active control drug together. When ‘asymptomatic hypoglycemia symptoms’ were included, there were 32 patients (31.37%) in the group administered metformin, glimepiride, and teneligliptin in combination, and 28 patients (28.57%) in the group administered metformin, glimepiride, and active control drug in combination. Among the reported hypoglycemias, severe hypoglycemia occurred in one person each in the test and control groups.
(3) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,042 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.54% (199/3,042 people, 263 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
*Table: Refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to manual
<Additional information on individual ingredients>
teneligliptin
The safety of a total of 142 subjects was analyzed in a randomized, double-blind, parallel group, placebo-controlled, phase 3 clinical trial conducted in Korea.
During the 24 weeks of the clinical trial, the adverse reaction rate was 45.45% (20/44 people) in the placebo group and 29.59% (29/98 people) in the teneligliptin group, and the adverse reaction rate was 6.82% (3/44 people) in the placebo group and 1.02% (1/98 people) in the teneligliptin group. The differences between groups in the incidence of adverse reactions and adverse drug reactions were not statistically significant. The adverse drug reaction was dyslipidemia. As a result of clinical trials, adverse reactions reported at a frequency of 2% or more, which occurred more frequently in patients receiving teneligliptin than in patients receiving placebo, are shown in Table 4.
Table 4. Teneligliptin monotherapy clinical trial results, adverse reactions reported at a frequency of 2% or more occurred more frequently in patients receiving teneligliptin compared to placebo (regardless of investigator causality assessment)
*Table: Refer to manual
metformin hydrochloride
In placebo-controlled monotherapy trials of extended-release metformin, diarrhea and nausea/vomiting were reported in >5% of metformin-treated patients and more commonly in placebo-controlled patients (diarrhea 9.6% vs 2.6%, nausea/vomiting 6.5% vs 1.5%). Diarrhea caused discontinuation of the test drug in 0.6% of patients receiving sustained-release metformin.
Additionally, metformin may lower serum vitamin B12 concentrations. It is recommended that patients taking this drug undergo a hematological test every year, and if there are any obvious abnormalities, they should be appropriately investigated and managed.
<Domestic post-marketing survey results>
As a result of a post-marketing survey conducted on 633 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 6.0% (38/633 people, 54 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to causal relationships are listed in the table below according to frequency of occurrence, and no serious adverse drug reactions for which causal relationships cannot be ruled out were reported.
*Table: Refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to manual
5. General precautions
1) Lactic acidosis
Lactic acidosis is a rare but serious metabolic complication that occurs due to accumulation of metformin hydrochloride during treatment. In 50% of cases it occurs, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin hydrochloride is believed to be the cause of lactic acidosis, the blood concentration of metformin hydrochloride is generally found to exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin hydrochloride (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple internal and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin hydrochloride should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so metformin hydrochloride is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to cause metformin hydrochloride to affect lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while receiving metformin hydrochloride.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin hydrochloride concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a certain dose of metformin hydrochloride, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin hydrochloride do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient receiving metformin hydrochloride, the drug should be discontinued immediately and general supportive therapy should be immediately administered. Since metformin hydrochloride is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Monitoring of renal function
Metformin is mostly excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal dysfunction. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), discontinue treatment. Special caution is needed in situations that may lead to rapid renal function impairment, such as those experiencing dehydration (severe or persistent vomiting or diarrhea) or starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
3) Liver dysfunction
The administration of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Therefore, this drug is not administered to patients with hepatic impairment.
4) Diabetes-like symptoms
Application is considered only for patients with confirmed type 2 diabetes. Please note that in addition to diabetes, there are diseases that show diabetes-like symptoms (nephrogenic diabetes, abnormal thyroid function, etc.), such as impaired glucose tolerance and positive urine glucose.
5) Hypoxia state
Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia have been associated with lactic acidosis with metformin administration and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
6) Alcohol consumption
Alcohol is known to increase the effect of metformin hydrochloride on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level
In clinical trials lasting 29 weeks, approximately 7% of patients receiving metformin hydrochloride were observed to have normal serum vitamin B12 levels decline below normal before the trial, without clinical symptoms. However, this decrease is possible because it interferes with B12 absorption from the B12-intrinsic factor complex, has little correlation with anemia, and is quickly recovered by discontinuing metformin hydrochloride administration or supplementing with vitamin B12. Patients receiving metformin hydrochloride should have their hematological values checked annually, and obvious abnormal values should be appropriately evaluated and managed. Certain individuals (those with inadequate intake or absorption of vitamin B12 or calcium) may be predisposed to having vitamin B12 levels below normal. For these patients, it may be useful to have regular serum vitamin B12 measurements at 2-3 year intervals.
8) Changes in controlled diabetes patients
If a patient whose type 2 diabetes was previously well controlled with this drug develops abnormal laboratory findings or clinical disease (especially vague and poorly defined disease), the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin hydrochloride levels are tested. If any form of acidosis appears, immediately stop administering metformin hydrochloride and take other appropriate and correct measures.
9) Concurrent administration with drugs known to cause hypoglycemia
If this drug is used together with insulin secretion stimulants such as insulin and sulfonylureas, the incidence of hypoglycemia may increase. When used in combination with sulfonylurea drugs or insulin, a reduction in the amount of sulfonylurea drugs or insulin may be considered to reduce the risk of hypoglycemia. When using this medicine, fully explain to the patient the symptoms of hypoglycemia and how to deal with it.
10) Patients from specific occupations
Metformin, one of the ingredients of this drug, may rarely cause severe lactic acidosis and severe delayed hypoglycemia, so caution should be exercised when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
In rare cases, it may cause severe lactic acidosis and severe delayed hypoglycemia, so caution should be exercised when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
11) Concomitant medications that affect renal function or metformin distribution
Concomitant medications that affect metformin distribution, such as cationic drugs that affect renal function, cause significant hemodynamic changes, or are eliminated by renal tubular secretion, should be administered with caution.
12) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking other DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
13) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and a dermatologist should be consulted for diagnosis and appropriate treatment.
6. Interaction
Studies on the pharmacokinetic drug interactions of this drug have not been conducted, but studies have been conducted on teneligliptin and metformin, respectively.
teneligliptin
Teneligliptin is mainly metabolized by CYP3A4 and flavin-containing monooxygenase (FMO1 and FMO3), and the excretion rate of unmetabolized teneligliptin through urine was 14.8-22.1%.
1) Ketoconazole: When ketoconazole, a strong CYP3A4 inhibitor and P-gp inhibitor, was coadministered with 20 mg of teneligliptin, the AUC and Cmax of teneligliptin increased by 1.49-fold and 1.37-fold, respectively.
2) Metformin: When teneligliptin 40mg and metformin were administered together, metformin did not significantly change the pharmacokinetics of teneligliptin. In addition, by co-administering teneligliptin, the AUC of metformin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.209 [1.143∼1.278]), but Cmax did not change. It is thought unlikely that teneligliptin will have a significant effect on the pharmacokinetics of metformin.
3) Sulfonylurea: When teneligliptin 40mg and glimepiride were co-administered, no drug interaction between teneligliptin and glimepiride was confirmed.
4) Thiazolidinedione: When teneligliptin 40mg and pioglitazone were co-administered, teneligliptin did not significantly change the pharmacokinetics of pioglitazone and its active metabolites (M-III and M-IV). In addition, the Cmax of teneligliptin showed a slight increase (geometric least squares mean ratio [90% CI]: 1.117 [0.984∼1.266]) by co-administering pioglitazone, but the AUC did not change. There appears to be little effect of coadministration with pioglitazone on the pharmacokinetics of teneligliptin.
5) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be further increased by drugs that increase the blood sugar lowering effect such as β-blockers, salicylates, and MAO inhibitors, so it should be administered while sufficiently observing the blood sugar level and patient condition.
6) Like other oral diabetes drugs, the blood sugar lowering effect of teneligliptin can be reduced by drugs that reduce the blood sugar lowering effect such as adrenaline, corticosteroids, and thyroid hormones, so it should be administered while sufficiently observing the blood sugar level and patient condition.
7) There is a risk of QT interval prolongation when coadministered with arrhythmia drugs of class IA (e.g., quinidine, procainamide) or group III (e.g., amiodarone, sotalol) that may cause QT interval prolongation.
metformin hydrochloride
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, angiotensin converting enzyme inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.),
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and potentially expose patients to the risk of lactic acidosis. Metformin administration should be discontinued before or at the time of testing using iodine-labeled contrast media, and administered again at least 48 hours later and after confirmation of normal renal function.
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin hydrochloride and glyburide did not change the pharmacokinetics or pharmacodynamic properties of metformin hydrochloride. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose metformin hydrochloride in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction of metformin hydrochloride and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin hydrochloride without significant changes in the renal clearance of metformin hydrochloride, and increases blood Cmax by 22% and blood AUC by 15%. When administered together with metformin hydrochloride, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin hydrochloride and furosemide are co-administered chronically.
6) Nifedipine: A study on the drug interaction between metformin hydrochloride and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin hydrochloride in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin hydrochloride. Metformin hydrochloride does not significantly affect nifedipine.
7) Drugs that may affect metformin hydrochloride, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In a single co-administration study in healthy volunteers, the pharmacokinetic properties of metformin hydrochloride and propranolol, and metformin hydrochloride and ibuprofen were not affected by each other. Since the binding of metformin hydrochloride to plasma proteins is negligible, there is little interaction with drugs that bind to proteins in large quantities, such as salicylic acid, sulfonamides, chloramphenicol, and probenecid, compared to sulfonylureas, which bind extensively to plasma proteins.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
Comparative clinical trials in pregnant women have not been conducted for this drug or each of its ingredients. Animal reproductive toxicity tests cannot predict reactions in humans. Therefore, it should not be administered to pregnant women or women who may be pregnant.
teneligliptin
There are no appropriate clinical trial results for pregnant women, so its use in pregnant women is not recommended. This drug has been observed to transfer to the fetus in non-clinical studies (rats).
metformin hydrochloride
Metformin was not teratogenic when administered to rats and rabbits at doses up to 600 mg/kg/day. This represents exposures approximately 2 and 6 times the maximum recommended human dose of 2000 mg based on body surface area comparisons in rats and rabbits, respectively. Partial placental passage of metformin was confirmed by measuring the concentration of the substance in the fetus.
2) Administration to nursing mothers
There have been no studies conducted on lactating animals with this drug combination. It is not known whether teneligliptin or metformin are excreted in human breast milk, but they have been reported to be excreted in breast milk in non-clinical studies (rats). Metformin is excreted in breast milk, and no adverse reactions to metformin have been reported in newborns/infants. However, due to limited reported study results, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in children have not been established (no clinical experience).
9. Administration to elderly people
Metformin is mainly excreted through the kidneys, and renal function tends to decline in the elderly, so the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should have their renal function monitored regularly, and maximum doses are generally not administered to elderly patients.
10. Treatment in case of overdose
teneligliptin
There were no cases of overdose in clinical trials conducted domestically and overseas. The highest dose of teneligliptin used in clinical trials is 320 mg administered to healthy adults for single administration, and 80 mg administered once daily for 7 days for repeated administration to healthy adults. No serious adverse reactions or adverse reactions leading to discontinuation of administration were identified at these doses.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
In patients with end-stage renal failure, 15.6% of the administered teneligliptin dose was removed during hemodialysis.
metformin hydrochloride
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
teneligliptin
1) For teneligliptin, a reverse mutation test using bacteria, a chromosomal abnormality test using CHL/IU cells, a rat micronucleus test, and an irregular DNA synthesis test in rats were conducted. In the chromosomal abnormality test, an increase in structural abnormalities, which appears to be a secondary change in cytotoxicity, was confirmed, but other tests did not cause abnormal mutations, so there appears to be no risk of genotoxicity.
2) As a result of evaluating carcinogenicity using rats and mice, carcinogenicity was not confirmed even at the dose considered to be the maximum tolerated dose (male rat: 75 mg/kg/day, female rat 100 mg/kg/day, mouse: 600 mg/kg/day). The highest doses evaluated in rats and mice represent 65- and 118-fold greater exposure compared to humans at 40 mg/day. The non-toxic dose for non-neoplastic lesions was 10 mg/kg/day and 60 mg/kg/day in rats and mice, respectively (corresponding to approximately 4 times the exposure of 40 mg per day in humans).
3) In a reproductive toxicity test conducted using rats, the non-toxic dose for male and female fertility and reproductive performance was 70 mg/kg/day and 100 mg/kg/day, respectively, which is 11 to 45 times the exposure amount compared to 40 mg/day administered to the human body. In embryo-fetal developmental toxicity tests conducted using rats and rabbits, no teratogenic findings were confirmed in both species, and the non-toxic dose for developmental toxicity is 30 mg/kg/day, which is approximately 11 and 16 times the exposure to humans administered at 40 mg/day. In tests on prenatal and postnatal development and maternal function conducted using rats, the non-toxic dose was 30 mg/kg/day, which is approximately 11 times the exposure amount compared to 40 mg/day administered to humans.
4) In a foreign clinical trial, teneligliptin 160mg was administered repeatedly for 4 days once a day to healthy adults. At this time, placebo-adjusted mean QTc interval prolongation was observed for each individual up to 9.3 msec (90% CI upper limit 13.0 msec). There is no experience in administering more than 160 mg per day in humans.
metformin hydrochloride
1) Metformin is a primary or secondary regenerating drug and does not exhibit pharmacokinetic properties that cause addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (dose lasting 91 weeks) at doses of 900mg/kg/day and 1500mg/kg/day, respectively. This dose is approximately four times the human body's maximum daily allowance based on body surface area. There was no evidence of metformin-related carcinogenicity in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence of the mutagenic potential of this drug in the reverse mutation test (S.typhimurim), gene mutation test (mouse lymphoma cells), chromosomal aberration test (human lymphocytes), or in vivo micronucleus test (mouse bone marrow cells).
Fertility of male and female rats was not affected by metformin when administered at a high dose of 600 mg/kg/day, or approximately 3 times the maximum tolerated dose based on body surface area.
13. Information for experts
1) Pharmacological action
This drug is a combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin.
2) Pharmacokinetic information
A. fasting test
In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Teneri-M 20/1000 mg extended-release tablets (KyungDong Pharm Co., Ltd.), and the reference product, Tenelia-M 20/1000 mg extended-release tablets (Handok Inc.), under fasting conditions. Plasma teneligliptin and metformin concentrations were measured in 38 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
* Table: refer to manual
B. Postprandial test
The test drug Tenelia M extended-release tablets 20/1000 mg [KyungDong Pharm Co., Ltd.] and the control drug Tenelia M extended-release tablets 20/1000 mg [Handok Co., Ltd.] were administered orally once to healthy adults after a meal in a 2 In this case, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
* Table: refer to manual
c. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drugs TeneriM Extended-Release Tablet 10/500 mg [KyungDong Pharm Co., Ltd.] and TeneriM Extended-Release Tablet 10/750 mg [KyungDong Pharm Co., Ltd.] with the reference drug TeneriM Extended-Release Tablet 20/1000 mg [KyungDong Pharm Co., Ltd.], and the dissolution patterns were equivalent to the reference drug. Accordingly, bioequivalence was proven with the relevant data.
3) Clinical trial information (Tenelia M-sero-release tablet)
Add-on combination of teneligliptin to metformin
The efficacy and safety of teneligliptin when combined with metformin were evaluated in a randomized, double-blind, multicenter, placebo-controlled clinical trial involving a total of 207 patients with type 2 diabetes (HbA1c 7% to less than 10%) who had poor glycemic control with metformin monotherapy (daily dose of 1,000 mg or more for 8 weeks or more). Patients were randomly assigned to receive teneligliptin 20 mg or placebo once daily after a 2-week single-blind, placebo run-in period while continuing metformin treatment.
After 16 weeks of treatment, glycated hemoglobin (HbA1c) in the teneligliptin and metformin combination group was statistically significantly reduced compared to the placebo and metformin combination group, and the proportion of patients whose glycated hemoglobin (HbA1c) reached less than 7% was statistically significantly higher than the placebo and metformin combination group [see Table 3].
Table 3. 16-week treatment results in a placebo-controlled clinical trial of the addition of teneligliptin to metformin in patients with type 2 diabetes.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
18 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | TenelyM SR Tab. 10/750mg | Precautions for use | 2023.06.14 | PDFTenerium extended-release tablets 10_500mg, 10_750mg, 20_1000mg Precautions for use (draft).pdf |